vasopeptidase inhibitors (BMS)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namevasopeptidase inhibitors (BMS)
Drug Alias Namedual NEP/ACE inhibitors (BMS)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin-converting enzyme inhibitorsMatrix metalloproteinase inhibitors
TargetsMatrix metalloproteinaseAngiotensin-converting enzyme
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A